Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

NCT06948955 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT06948955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Lead sponsor
Cogent Biosciences, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasms, gastrointestinal stromal tumors